{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"47"}]}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"77"}]}],"title":"Month 18"}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"description":"PD (for patients not in CR) required one or more of the following:\n\n* 25% increase in serum monoclonal paraprotein level, 24-hour urinary light chain excretion, or plasma cells;\n* Increase in size of existing or development of new bone lesions/soft tissue plasmacytomas;\n* Development of hypercalcemia.\n\nRelapse from CR required at least one of the following:\n\n* Reappearance of serum or urinary paraprotein;\n* \\>5% plasma cells;\n* Development of new lytic bone lesions or soft tissue plasmacytomas or increase in the size of residual bone lesions;\n* Development of hypercalcemia.","groups":[{"description":"Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.","id":"OG000","title":"Peginterferon α-2b"},{"description":"Participants were observed and received no treatment","id":"OG001","title":"No Treatment"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population (those who received at least one dose of study drug)","reportingStatus":"POSTED","timeFrame":"Month 9 & Month 18","title":"Number of Participants With Progressive Disease(PD) or Relapse From CR","type":"SECONDARY","unitOfMeasure":"Participants"}